SLC5A2 and Obesity: The salutary effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors, like empagliflozin, on diabetes-related hyperglycaemia, obesity and hypertension may be at least in part mediated by the reduction of glomerular hyperfiltration via activation of A1AR receptors and TGF-mediated afferent arteriolar vasoconstriction, independently of their ability to lower the plasma glucose levels (Kidokoro et al., 2019).